Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
9.27
-0.14 (-1.49%)
At close: Sep 25, 2026, 4:00 PM EDT
9.25
-0.02 (-0.22%)
After-hours: Sep 25, 2026, 7:30 PM EDT
Oculis Holding AG Employees
Oculis Holding AG had 60 employees as of December 31, 2025. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
$24,196
Profits / Employee
-$1,633,457
Market Cap
572.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 60 | 11 | 22.45% |
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
| Sep 30, 2022 | 32 | - | - |
| Jun 30, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Phathom Pharmaceuticals | 371 |
| CorMedix | 191 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| MapLight Therapeutics | 133 |
| CytomX Therapeutics | 69 |
| Crescent Biopharma | 69 |
OCS News
- 9 days ago - Oculis price target raised to $39 from $26 at H.C. Wainwright - TheFly
- 10 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 12 days ago - Oculis Holding AG Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Oculis Holding AG Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - GlobeNewsWire
- 6 weeks ago - Oculis price target lowered to $20 from $23 at JPMorgan - TheFly
- 6 weeks ago - Oculis price target lowered to $32 from $35 at BofA - TheFly
- 6 weeks ago - Oculis to acquire development, commercial rights to Privosegtor from Accure - TheFly